Cargando…

Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern. At present, there is no specific antiviral treatment recommended for SARS-CoV-2 infection. Liu Shen capsule (LS), a traditio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Qinhai, Pan, Weiqi, Li, Runfeng, Liu, Bin, Li, Chufang, Xie, Yuqi, Wang, Zhoulang, Zhao, Jin, Jiang, Haiming, Huang, Jicheng, Shi, Yongxia, Dai, Jun, Zheng, Kui, Li, Xiaobo, Yang, Zifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192119/
https://www.ncbi.nlm.nih.gov/pubmed/32360580
http://dx.doi.org/10.1016/j.phrs.2020.104850
_version_ 1783527965604184064
author Ma, Qinhai
Pan, Weiqi
Li, Runfeng
Liu, Bin
Li, Chufang
Xie, Yuqi
Wang, Zhoulang
Zhao, Jin
Jiang, Haiming
Huang, Jicheng
Shi, Yongxia
Dai, Jun
Zheng, Kui
Li, Xiaobo
Yang, Zifeng
author_facet Ma, Qinhai
Pan, Weiqi
Li, Runfeng
Liu, Bin
Li, Chufang
Xie, Yuqi
Wang, Zhoulang
Zhao, Jin
Jiang, Haiming
Huang, Jicheng
Shi, Yongxia
Dai, Jun
Zheng, Kui
Li, Xiaobo
Yang, Zifeng
author_sort Ma, Qinhai
collection PubMed
description Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern. At present, there is no specific antiviral treatment recommended for SARS-CoV-2 infection. Liu Shen capsule (LS), a traditional Chinese medicine, has been proven to have a wide spectrum of pharmacological properties, such as anti-inflammatory, antiviral and immunomodulatory activities. However, little is known about the antiviral effect of LS against SARS-CoV-2. Herein, the study was designed to investigate the antiviral activity of SARS-CoV-2 and its potential effect in regulating the host’s immune response. The inhibitory effect of LS against SARS-CoV-2 replication in Vero E6 cells was evaluated by using the cytopathic effect (CPE) and plaque reduction assay. The number of virions of SARS-CoV-2 was observed under transmission electron microscope after treatment with LS. Proinflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays. The results showed that LS could significantly inhibit SARS-CoV-2 replication in Vero E6 cells, and reduce the number of virus particles and it could markedly reduce pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-8, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Moreover, the expression of the key proteins in the NF-κB/MAPK signaling pathway was detected by western blot and it was found that LS could inhibit the expression of p-NF-κB p65, p-IκBα and p-p38 MAPK, while increasing the expression of IκBα. These findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-κB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease.
format Online
Article
Text
id pubmed-7192119
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71921192020-04-30 Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway Ma, Qinhai Pan, Weiqi Li, Runfeng Liu, Bin Li, Chufang Xie, Yuqi Wang, Zhoulang Zhao, Jin Jiang, Haiming Huang, Jicheng Shi, Yongxia Dai, Jun Zheng, Kui Li, Xiaobo Yang, Zifeng Pharmacol Res Article Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern. At present, there is no specific antiviral treatment recommended for SARS-CoV-2 infection. Liu Shen capsule (LS), a traditional Chinese medicine, has been proven to have a wide spectrum of pharmacological properties, such as anti-inflammatory, antiviral and immunomodulatory activities. However, little is known about the antiviral effect of LS against SARS-CoV-2. Herein, the study was designed to investigate the antiviral activity of SARS-CoV-2 and its potential effect in regulating the host’s immune response. The inhibitory effect of LS against SARS-CoV-2 replication in Vero E6 cells was evaluated by using the cytopathic effect (CPE) and plaque reduction assay. The number of virions of SARS-CoV-2 was observed under transmission electron microscope after treatment with LS. Proinflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays. The results showed that LS could significantly inhibit SARS-CoV-2 replication in Vero E6 cells, and reduce the number of virus particles and it could markedly reduce pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-8, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Moreover, the expression of the key proteins in the NF-κB/MAPK signaling pathway was detected by western blot and it was found that LS could inhibit the expression of p-NF-κB p65, p-IκBα and p-p38 MAPK, while increasing the expression of IκBα. These findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-κB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease. Elsevier Ltd. 2020-08 2020-04-30 /pmc/articles/PMC7192119/ /pubmed/32360580 http://dx.doi.org/10.1016/j.phrs.2020.104850 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ma, Qinhai
Pan, Weiqi
Li, Runfeng
Liu, Bin
Li, Chufang
Xie, Yuqi
Wang, Zhoulang
Zhao, Jin
Jiang, Haiming
Huang, Jicheng
Shi, Yongxia
Dai, Jun
Zheng, Kui
Li, Xiaobo
Yang, Zifeng
Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
title Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
title_full Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
title_fullStr Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
title_full_unstemmed Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
title_short Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
title_sort liu shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus sars-cov-2 via suppression of nf-κb signaling pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192119/
https://www.ncbi.nlm.nih.gov/pubmed/32360580
http://dx.doi.org/10.1016/j.phrs.2020.104850
work_keys_str_mv AT maqinhai liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT panweiqi liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT lirunfeng liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT liubin liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT lichufang liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT xieyuqi liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT wangzhoulang liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT zhaojin liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT jianghaiming liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT huangjicheng liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT shiyongxia liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT daijun liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT zhengkui liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT lixiaobo liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway
AT yangzifeng liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway